These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1286518)

  • 1. Hormonal management of prostate cancer.
    Wasan HS; Waxman J
    Clin Endocrinol (Oxf); 1992 Dec; 37(6):477-80. PubMed ID: 1286518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgens and prostate cancer: biology, pathology and hormonal therapy.
    Galbraith SM; Duchesne GM
    Eur J Cancer; 1997 Apr; 33(4):545-54. PubMed ID: 9274433
    [No Abstract]   [Full Text] [Related]  

  • 3. Medical therapy of prostate cancer. A review.
    Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
    Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy: where do we stand and where are we going?
    Schröder FH
    Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To block or not to block-hormonal signaling in the treatment of cancers.
    Abikar A; Saimon C; Ranganathan P
    Front Endocrinol (Lausanne); 2023; 14():1129332. PubMed ID: 36891053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages of total androgen blockade in the treatment of advanced prostate cancer.
    Geller J; Albert J; Vik A
    Semin Oncol; 1988 Apr; 15(2 Suppl 1):53-61. PubMed ID: 3285484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
    Sharifi N; Dahut WL; Figg WD
    BJU Int; 2008 Feb; 101(3):271-4. PubMed ID: 17922868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An organ-culture technique for the investiation of hormonal dependence in human prostatic neoplasia.
    McMahon MJ; Thomas GH
    Br J Surg; 1970 Nov; 57(11):860. PubMed ID: 4098286
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hormonal therapy for advanced prostate cancer: current status and issues].
    Akakura K
    Nihon Rinsho; 2016 Jan; 74(1):124-8. PubMed ID: 26793892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer.
    Verhelst J; Denis L; Van Vliet P; Van Poppel H; Braeckman J; Van Cangh P; Mattelaer J; D'Hulster D; Mahler C
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):525-30. PubMed ID: 7525125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma of the prostate: early endocrine therapy is best.
    Spirnak JP; Resnick MI
    Semin Urol; 1983 Nov; 1(4):269-79. PubMed ID: 6399613
    [No Abstract]   [Full Text] [Related]  

  • 15. Altered association of interleukin-6 with sex steroids in lipid metabolism disorder in men with prostate cancer receiving androgen deprivation therapy.
    Komatsu S; Hara N; Ishizaki F; Nishiyama T; Takizawa I; Isahaya E; Kawasaki T; Takahashi K
    Prostate; 2012 Aug; 72(11):1207-13. PubMed ID: 22213519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.
    Duchesne GM; Woo HH; Bassett JK; Bowe SJ; D'Este C; Frydenberg M; King M; Ledwich L; Loblaw A; Malone S; Millar J; Milne R; Smith RG; Spry N; Stockler M; Syme RA; Tai KH; Turner S
    Lancet Oncol; 2016 Jun; 17(6):727-737. PubMed ID: 27155740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-prostatic androgen levels during various androgen-blockade regimens.
    Nishiyama T
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):229-41. PubMed ID: 18471782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Androgen deprivation therapy in locally advanced prostate cancer].
    Rossi D; Beuzeboc P; Staerman F; Timsit MO; Benchikh El Fegoun A
    Prog Urol; 2010 Mar; 20 Suppl 1():S68-71. PubMed ID: 20493450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.